Oncomatryx, a Zamudio, Spain-based global bio-pharmaceutical company, acquired Tube Pharmaceuticals GmbH, the Austrian developer of the Cytolysintoxic payload.
The amount of the deal was not disclosed.
The multimillion euro transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment.
Oncomatryx’s pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class antibody-drug conjugate targeting cancer-associated fibroblasts. A FIH multiple expansion cohort clinical trial targeting metastatic solid tumors is ongoing in seven hospitals in Spain and USA. The company now owns the comprehensive portfolio of cytolysins synthesized by Tube and the technology developed in its laboratories.
Led by Dr. Wolfgang Richter, Tube Pharmaceuticals has more than 15 years of experience and has positioned itself as a top-level benchmark in the generation of novel ADC payloads. Dr. Richter will drive the company’s efforts to continue developing novel drugs that attack the tumor microenvironment.
Led by Laureano Simon, founder, Oncomatryx is a global bio-pharmaceutical company that targets the microenvironment of the most invasive tumors through its next-generation precision ADCs, bispecific antibodies and small molecules. Located in the Bizkaia Technology Park, the company has discovered novel mechanisms and proteins in the tumor microenvironment that facilitate tumor invasiveness, immunosuppression, drug resistance and metastasis. Oncomatryx is investing 100 million euros to develop its pioneering tumor-microenvironment pipeline into clinical trials against these most invasive solid tumors.
FinSMEs
19/05/2023